CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Charles University in Prague
Praga, República ChecaPublicacións en colaboración con investigadores/as de Charles University in Prague (12)
2024
-
Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness z Scores
Neurology: Neuroimmunology and NeuroInflammation, Vol. 11, Núm. 5
2022
-
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846
-
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180
Computer methods and programs in biomedicine
2018
-
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
The Lancet Neurology, Vol. 17, Núm. 5, pp. 405-415
-
Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group
Multiple Sclerosis and Related Disorders, Vol. 19, pp. 153-160
2016
-
Defining secondary progressive multiple sclerosis
Brain, Vol. 139, Núm. 9, pp. 2395-2405
-
Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: A cohort study
The Lancet Neurology, Vol. 15, Núm. 6, pp. 574-584
2015
-
BREMSO: A simple score to predict early the natural course of multiple sclerosis
European Journal of Neurology, Vol. 22, Núm. 6, pp. 981-989
-
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
JAMA Neurology, Vol. 72, Núm. 4, pp. 405-413
-
Defining reliable disability outcomes in multiple sclerosis
Brain, Vol. 138, Núm. 11, pp. 3287-3298
-
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
Annals of Neurology, Vol. 77, Núm. 3, pp. 425-435
2013
-
Future MS care: A consensus statement of the MS in the 21st Century Steering Group
Journal of Neurology, Vol. 260, Núm. 2, pp. 462-469